In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...

(Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs ...

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively ...

Peter Wickersham is the Vice President and General Manager of Gilead Sciences UK & Ireland, and a leader in HIV treatment, liver disease, and oncology. With over 25 years in healthcare ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The stock's rise snapped a five-day losing streak.

We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks.